Indications for MYCAPSSA:
Long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Swallow whole. Take on an empty stomach (≥1hr before or ≥2hrs after a meal). Initially 20mg twice daily; titrate and increase in 20mg increments, based on IGF-1 levels and response; max 80mg/day. Dose interruptions/modifications: see full labeling. ESRD: initially 20mg once daily.
Diabetes. Thyroid function abnormalities. Assess thyroid function periodically. Cardiac conduction abnormalities. Monitor gallbladder, glucose, vitamin B12 levels. Discontinue and treat if cholelithiasis complications are suspected. Monitor IGF-1 levels every 2 weeks during dose titration and monthly when maintenance dose is achieved, or as indicated. ESRD (see Adult dose). Liver cirrhosis. Fatty liver disease. Elderly. Pregnancy. Nursing mothers.
Concomitant bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers); may need dose adjustments. Potentiates bromocriptine, CYP450 substrates (eg, quinidine), lisinopril; monitor and adjust dose if needed. Antagonized by PPIs, H2-receptor antagonists, or antacids; may need increased dose of Mycapssa. Antagonizes cyclosporine (adjust dose), digoxin (monitor). Antagonizes levonorgestrel (advise to use alternative non-hormonal contraceptive or back-up method). May need to adjust insulin or antidiabetic agents.
Nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, increased blood glucose, vomiting, abdominal discomfort, dyspepsia, sinusitis, osteoarthritis; gallbladder abnormalities/sludge, hyperglycemia, hypoglycemia, hypothyroidism, cardiac conduction abnormalities, ECG changes, abnormal Schilling's tests.
Generic Drug Availability: